European Regulatory Strategy ‘Should Prioritize Real World Evidence’
Innovative Clinical Trials Should Be Priority Too, Says EFPIA.
Executive Summary
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.
You may also be interested in...
Regulators Need New Skills & Smarter Guidance To Govern AI, Says EMA Chief
A two-day workshop saw EU policymakers and regulators meet with dozens of representatives from the pharmaceutical, health and medtech industries to discuss the future of regulating AI in medicine and its uses in the medicinal product lifecycle.
EMA Fee Proposals Pass Another Legislative Milestone
Agreement on a new, more streamlined fee structure for the European regulator could be reached by the end of this year.
EU Drug Regulatory Network Faces Up To An Uncertain And Complex Future
Regulators have produced yet another strategy outlining the challenges and next steps for the European drug regulatory network as the network prepares for a future characterized by rapid developments in science and technology, medicines access issues, supply chain weaknesses and emerging health threats.